Davita Inc (NYSE:DVA) Shares Sold by California State Teachers Retirement System
California State Teachers Retirement System reduced its stake in Davita Inc (NYSE:DVA) by 3.0% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 209,319 shares of the company’s stock after selling 6,400 shares during the period. California State Teachers Retirement System’s holdings in Davita were worth $11,946,000 as of its most recent SEC filing.
Several other large investors also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of Davita by 0.5% in the 2nd quarter. Vanguard Group Inc. now owns 13,652,940 shares of the company’s stock worth $768,114,000 after purchasing an additional 64,415 shares during the last quarter. Par Capital Management Inc. lifted its stake in Davita by 40.6% in the second quarter. Par Capital Management Inc. now owns 4,159,000 shares of the company’s stock valued at $233,985,000 after buying an additional 1,201,300 shares during the last quarter. Invesco Ltd. lifted its stake in Davita by 56.2% in the second quarter. Invesco Ltd. now owns 3,662,685 shares of the company’s stock valued at $206,063,000 after buying an additional 1,317,725 shares during the last quarter. Viking Global Investors LP boosted its holdings in shares of Davita by 5.5% during the second quarter. Viking Global Investors LP now owns 2,907,034 shares of the company’s stock valued at $163,550,000 after acquiring an additional 151,529 shares during the period. Finally, Camber Capital Management LP boosted its holdings in shares of Davita by 33.3% during the second quarter. Camber Capital Management LP now owns 2,000,000 shares of the company’s stock valued at $112,520,000 after acquiring an additional 500,000 shares during the period. 94.41% of the stock is owned by institutional investors.
A number of research firms recently weighed in on DVA. Sanford C. Bernstein began coverage on shares of Davita in a report on Tuesday, November 12th. They issued a “market perform” rating on the stock. Wolfe Research downgraded shares of Davita from an “outperform” rating to a “market perform” rating and set a $57.00 price objective on the stock. in a research report on Friday, October 25th. UBS Group reduced their target price on shares of Davita from $61.00 to $60.00 and set a “neutral” rating for the company in a research note on Thursday, August 22nd. William Blair cut shares of Davita from an “outperform” rating to a “market perform” rating in a research report on Wednesday, September 11th. Finally, SunTrust Banks raised their price target on shares of Davita to $72.00 and gave the company a “hold” rating in a research note on Wednesday, November 6th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $65.00.
Davita (NYSE:DVA) last announced its earnings results on Tuesday, November 5th. The company reported $1.53 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.24 by $0.29. Davita had a return on equity of 19.95% and a net margin of 3.68%. The firm had revenue of $2.90 billion for the quarter, compared to analysts’ expectations of $2.85 billion. During the same quarter in the previous year, the company earned $0.56 earnings per share. The firm’s quarterly revenue was up 2.0% compared to the same quarter last year. On average, analysts forecast that Davita Inc will post 5.31 earnings per share for the current fiscal year.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Davita Inc (NYSE:DVA).
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.